Data on the detection of clinically significant prostate cancer by magnetic resonance imaging (MRI)-guided targeted and systematic biopsy

This is a data article from the original publication Rea-sons for missing clinically significant prostate cancer by tar-geted magnetic resonance imaging/ultrasound fusion-guided biopsy [1] . From January 2014 to April 2019 a sample collec-tive of 785 patients with 3T multiparametric magnetic res-onance imaging (mp-MRI) of the prostate and subsequent combined systematic biopsy (SB) and magnetic resonance imaging/ultrasound (US) fusion-guided biopsy (TB) was ret-rospectively analyzed. Prostate cancer (PCa) detection by TB and/or additional SB was analyzed.(c) 2022 The Authors. Published by Elsevier Inc.This is an open access article under the CC BY license ( http://creativecommons.org/licenses/by/4.0/ )

Automated summary

This data article retrospectively analyzed the effectiveness of magnetic resonance imaging/ultrasound-guided biopsy in detecting clinically significant prostate cancer based on a sample collective of 785 patients.